Industry Research Reports

Home > Reports > Pharma & Healthcare > 23-valent Pneumococcal Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

23-valent Pneumococcal Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Pharma & Healthcare

Published: 2024-01-13

Pages: 101 Pages

Report ld: 2630422

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

The global market for 23-valent Pneumococcal Vaccine was estimated to be worth US$ 1440 million in 2023 and is forecast to a readjusted size of US$ 1938.4 million by 2030 with a CAGR of 4.4% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

23-valent Pneumococcal Vaccine Market Size

M= millions and B=billions

Report Scope
This report aims to provide a comprehensive presentation of the global market for 23-valent Pneumococcal Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of 23-valent Pneumococcal Vaccine by region & country, by Type, and by Application.

The 23-valent Pneumococcal Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding 23-valent Pneumococcal Vaccine.

Market Segmentation

Report Metric
Details
Report Title
23-valent Pneumococcal Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Forecasted Market Size in 2030
US$ 1938.4 million
CAGR(2024-2030)
4.4%
Market Size Available for Years
2019-2030
Global 23-valent Pneumococcal Vaccine Companies Covered
Merck, Sanofipasteur, CDIBP, Kexing Bio, Changsheng Bio-Technology, Huaan Science and Technology Innovation
Global 23-valent Pneumococcal Vaccine Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global 23-valent Pneumococcal Vaccine Market, Segment by Type
Single Dose Vial

Pre-filled Syringe
Global 23-valent Pneumococcal Vaccine Market, Segment by Application
Chronic Cardiovascular Disease

Chronic Lung Disease

Chronic Liver Disease

People Living with Hiv

Leukemia

Lymphoma

Multiple Myeloma

General Malignancy

Chronic Kidney Disease

Other
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of 23-valent Pneumococcal Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of 23-valent Pneumococcal Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of 23-valent Pneumococcal Vaccine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 23-valent Pneumococcal Vaccine Product Introduction
    1.2 Global 23-valent Pneumococcal Vaccine Market Size Forecast
        1.2.1 Global 23-valent Pneumococcal Vaccine Sales Value (2019-2030)
        1.2.2 Global 23-valent Pneumococcal Vaccine Sales Volume (2019-2030)
        1.2.3 Global 23-valent Pneumococcal Vaccine Sales Price (2019-2030)
    1.3 23-valent Pneumococcal Vaccine Market Trends & Drivers
        1.3.1 23-valent Pneumococcal Vaccine Industry Trends
        1.3.2 23-valent Pneumococcal Vaccine Market Drivers & Opportunity
        1.3.3 23-valent Pneumococcal Vaccine Market Challenges
        1.3.4 23-valent Pneumococcal Vaccine Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global 23-valent Pneumococcal Vaccine Players Revenue Ranking (2023)
    2.2 Global 23-valent Pneumococcal Vaccine Revenue by Company (2019-2024)
    2.3 Global 23-valent Pneumococcal Vaccine Players Sales Volume Ranking (2023)
    2.4 Global 23-valent Pneumococcal Vaccine Sales Volume by Company Players (2019-2024)
    2.5 Global 23-valent Pneumococcal Vaccine Average Price by Company (2019-2024)
    2.6 Key Manufacturers 23-valent Pneumococcal Vaccine Manufacturing Base Distribution and Headquarters
    2.7 Key Manufacturers 23-valent Pneumococcal Vaccine Product Offered
    2.8 Key Manufacturers Time to Begin Mass Production of 23-valent Pneumococcal Vaccine
    2.9 23-valent Pneumococcal Vaccine Market Competitive Analysis
        2.9.1 23-valent Pneumococcal Vaccine Market Concentration Rate (2019-2024)
        2.9.2 Global 5 and 10 Largest Manufacturers by 23-valent Pneumococcal Vaccine Revenue in 2023
        2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in 23-valent Pneumococcal Vaccine as of 2023)
    2.10 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Single Dose Vial
        3.1.2 Pre-filled Syringe
    3.2 Global 23-valent Pneumococcal Vaccine Sales Value by Type
        3.2.1 Global 23-valent Pneumococcal Vaccine Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global 23-valent Pneumococcal Vaccine Sales Value, by Type (2019-2030)
        3.2.3 Global 23-valent Pneumococcal Vaccine Sales Value, by Type (%) (2019-2030)
    3.3 Global 23-valent Pneumococcal Vaccine Sales Volume by Type
        3.3.1 Global 23-valent Pneumococcal Vaccine Sales Volume by Type (2019 VS 2023 VS 2030)
        3.3.2 Global 23-valent Pneumococcal Vaccine Sales Volume, by Type (2019-2030)
        3.3.3 Global 23-valent Pneumococcal Vaccine Sales Volume, by Type (%) (2019-2030)
    3.4 Global 23-valent Pneumococcal Vaccine Average Price by Type (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Chronic Cardiovascular Disease
        4.1.2 Chronic Lung Disease
        4.1.3 Chronic Liver Disease
        4.1.4 People Living with Hiv
        4.1.5 Leukemia
        4.1.6 Lymphoma
        4.1.7 Multiple Myeloma
        4.1.8 General Malignancy
        4.1.9 Chronic Kidney Disease
        4.1.10 Other
    4.2 Global 23-valent Pneumococcal Vaccine Sales Value by Application
        4.2.1 Global 23-valent Pneumococcal Vaccine Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global 23-valent Pneumococcal Vaccine Sales Value, by Application (2019-2030)
        4.2.3 Global 23-valent Pneumococcal Vaccine Sales Value, by Application (%) (2019-2030)
    4.3 Global 23-valent Pneumococcal Vaccine Sales Volume by Application
        4.3.1 Global 23-valent Pneumococcal Vaccine Sales Volume by Application (2019 VS 2023 VS 2030)
        4.3.2 Global 23-valent Pneumococcal Vaccine Sales Volume, by Application (2019-2030)
        4.3.3 Global 23-valent Pneumococcal Vaccine Sales Volume, by Application (%) (2019-2030)
    4.4 Global 23-valent Pneumococcal Vaccine Average Price by Application (2019-2030)

 5 Segmentation by Region
    5.1 Global 23-valent Pneumococcal Vaccine Sales Value by Region
        5.1.1 Global 23-valent Pneumococcal Vaccine Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global 23-valent Pneumococcal Vaccine Sales Value by Region (2019-2024)
        5.1.3 Global 23-valent Pneumococcal Vaccine Sales Value by Region (2025-2030)
        5.1.4 Global 23-valent Pneumococcal Vaccine Sales Value by Region (%), (2019-2030)
    5.2 Global 23-valent Pneumococcal Vaccine Sales Volume by Region
        5.2.1 Global 23-valent Pneumococcal Vaccine Sales Volume by Region: 2019 VS 2023 VS 2030
        5.2.2 Global 23-valent Pneumococcal Vaccine Sales Volume by Region (2019-2024)
        5.2.3 Global 23-valent Pneumococcal Vaccine Sales Volume by Region (2025-2030)
        5.2.4 Global 23-valent Pneumococcal Vaccine Sales Volume by Region (%), (2019-2030)
    5.3 Global 23-valent Pneumococcal Vaccine Average Price by Region (2019-2030)
    5.4 North America
        5.4.1 North America 23-valent Pneumococcal Vaccine Sales Value, 2019-2030
        5.4.2 North America 23-valent Pneumococcal Vaccine Sales Value by Country (%), 2023 VS 2030
    5.5 Europe
        5.5.1 Europe 23-valent Pneumococcal Vaccine Sales Value, 2019-2030
        5.5.2 Europe 23-valent Pneumococcal Vaccine Sales Value by Country (%), 2023 VS 2030
    5.6 Asia Pacific
        5.6.1 Asia Pacific 23-valent Pneumococcal Vaccine Sales Value, 2019-2030
        5.6.2 Asia Pacific 23-valent Pneumococcal Vaccine Sales Value by Country (%), 2023 VS 2030
    5.7 South America
        5.7.1 South America 23-valent Pneumococcal Vaccine Sales Value, 2019-2030
        5.7.2 South America 23-valent Pneumococcal Vaccine Sales Value by Country (%), 2023 VS 2030
    5.8 Middle East & Africa
        5.8.1 Middle East & Africa 23-valent Pneumococcal Vaccine Sales Value, 2019-2030
        5.8.2 Middle East & Africa 23-valent Pneumococcal Vaccine Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions 23-valent Pneumococcal Vaccine Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions 23-valent Pneumococcal Vaccine Sales Value
        6.2.1 Key Countries/Regions 23-valent Pneumococcal Vaccine Sales Value, 2019-2030
        6.2.2 Key Countries/Regions 23-valent Pneumococcal Vaccine Sales Volume, 2019-2030
    6.3 United States
        6.3.1 United States 23-valent Pneumococcal Vaccine Sales Value, 2019-2030
        6.3.2 United States 23-valent Pneumococcal Vaccine Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States 23-valent Pneumococcal Vaccine Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe 23-valent Pneumococcal Vaccine Sales Value, 2019-2030
        6.4.2 Europe 23-valent Pneumococcal Vaccine Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe 23-valent Pneumococcal Vaccine Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China 23-valent Pneumococcal Vaccine Sales Value, 2019-2030
        6.5.2 China 23-valent Pneumococcal Vaccine Sales Value by Type (%), 2023 VS 2030
        6.5.3 China 23-valent Pneumococcal Vaccine Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan 23-valent Pneumococcal Vaccine Sales Value, 2019-2030
        6.6.2 Japan 23-valent Pneumococcal Vaccine Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan 23-valent Pneumococcal Vaccine Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea 23-valent Pneumococcal Vaccine Sales Value, 2019-2030
        6.7.2 South Korea 23-valent Pneumococcal Vaccine Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea 23-valent Pneumococcal Vaccine Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia 23-valent Pneumococcal Vaccine Sales Value, 2019-2030
        6.8.2 Southeast Asia 23-valent Pneumococcal Vaccine Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia 23-valent Pneumococcal Vaccine Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India 23-valent Pneumococcal Vaccine Sales Value, 2019-2030
        6.9.2 India 23-valent Pneumococcal Vaccine Sales Value by Type (%), 2023 VS 2030
        6.9.3 India 23-valent Pneumococcal Vaccine Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Merck
        7.1.1 Merck Company Information
        7.1.2 Merck Introduction and Business Overview
        7.1.3 Merck 23-valent Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
        7.1.4 Merck 23-valent Pneumococcal Vaccine Product Offerings
        7.1.5 Merck Recent Development
    7.2 Sanofipasteur
        7.2.1 Sanofipasteur Company Information
        7.2.2 Sanofipasteur Introduction and Business Overview
        7.2.3 Sanofipasteur 23-valent Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
        7.2.4 Sanofipasteur 23-valent Pneumococcal Vaccine Product Offerings
        7.2.5 Sanofipasteur Recent Development
    7.3 CDIBP
        7.3.1 CDIBP Company Information
        7.3.2 CDIBP Introduction and Business Overview
        7.3.3 CDIBP 23-valent Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
        7.3.4 CDIBP 23-valent Pneumococcal Vaccine Product Offerings
        7.3.5 CDIBP Recent Development
    7.4 Kexing Bio
        7.4.1 Kexing Bio Company Information
        7.4.2 Kexing Bio Introduction and Business Overview
        7.4.3 Kexing Bio 23-valent Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
        7.4.4 Kexing Bio 23-valent Pneumococcal Vaccine Product Offerings
        7.4.5 Kexing Bio Recent Development
    7.5 Changsheng Bio-Technology
        7.5.1 Changsheng Bio-Technology Company Information
        7.5.2 Changsheng Bio-Technology Introduction and Business Overview
        7.5.3 Changsheng Bio-Technology 23-valent Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
        7.5.4 Changsheng Bio-Technology 23-valent Pneumococcal Vaccine Product Offerings
        7.5.5 Changsheng Bio-Technology Recent Development
    7.6 Huaan Science and Technology Innovation
        7.6.1 Huaan Science and Technology Innovation Company Information
        7.6.2 Huaan Science and Technology Innovation Introduction and Business Overview
        7.6.3 Huaan Science and Technology Innovation 23-valent Pneumococcal Vaccine Sales, Revenue and Gross Margin (2019-2024)
        7.6.4 Huaan Science and Technology Innovation 23-valent Pneumococcal Vaccine Product Offerings
        7.6.5 Huaan Science and Technology Innovation Recent Development

 8 Industry Chain Analysis
    8.1 23-valent Pneumococcal Vaccine Industrial Chain
    8.2 23-valent Pneumococcal Vaccine Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 23-valent Pneumococcal Vaccine Sales Model
        8.5.2 Sales Channel
        8.5.3 23-valent Pneumococcal Vaccine Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. 23-valent Pneumococcal Vaccine Market Trends
    Table 2. 23-valent Pneumococcal Vaccine Market Drivers & Opportunity
    Table 3. 23-valent Pneumococcal Vaccine Market Challenges
    Table 4. 23-valent Pneumococcal Vaccine Market Restraints
    Table 5. Global 23-valent Pneumococcal Vaccine Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global 23-valent Pneumococcal Vaccine Revenue Market Share by Company (2019-2024)
    Table 7. Global 23-valent Pneumococcal Vaccine Sales Volume by Company (2019-2024) & (K Units)
    Table 8. Global 23-valent Pneumococcal Vaccine Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market 23-valent Pneumococcal Vaccine Price by Company (2019-2024) & (US$/Unit)
    Table 10. Key Manufacturers 23-valent Pneumococcal Vaccine Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers 23-valent Pneumococcal Vaccine Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of 23-valent Pneumococcal Vaccine
    Table 13. Global 23-valent Pneumococcal Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in 23-valent Pneumococcal Vaccine as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global 23-valent Pneumococcal Vaccine Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global 23-valent Pneumococcal Vaccine Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global 23-valent Pneumococcal Vaccine Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global 23-valent Pneumococcal Vaccine Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global 23-valent Pneumococcal Vaccine Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global 23-valent Pneumococcal Vaccine Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
    Table 22. Global 23-valent Pneumococcal Vaccine Sales Volume by Type (2019-2024) & (K Units)
    Table 23. Global 23-valent Pneumococcal Vaccine Sales Volume by Type (2025-2030) & (K Units)
    Table 24. Global 23-valent Pneumococcal Vaccine Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global 23-valent Pneumococcal Vaccine Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global 23-valent Pneumococcal Vaccine Price by Type (2019-2024) & (US$/Unit)
    Table 27. Global 23-valent Pneumococcal Vaccine Price by Type (2025-2030) & (US$/Unit)
    Table 28. Global 23-valent Pneumococcal Vaccine Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global 23-valent Pneumococcal Vaccine Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global 23-valent Pneumococcal Vaccine Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global 23-valent Pneumococcal Vaccine Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global 23-valent Pneumococcal Vaccine Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global 23-valent Pneumococcal Vaccine Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
    Table 34. Global 23-valent Pneumococcal Vaccine Sales Volume by Application (2019-2024) & (K Units)
    Table 35. Global 23-valent Pneumococcal Vaccine Sales Volume by Application (2025-2030) & (K Units)
    Table 36. Global 23-valent Pneumococcal Vaccine Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global 23-valent Pneumococcal Vaccine Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global 23-valent Pneumococcal Vaccine Price by Application (2019-2024) & (US$/Unit)
    Table 39. Global 23-valent Pneumococcal Vaccine Price by Application (2025-2030) & (US$/Unit)
    Table 40. Global 23-valent Pneumococcal Vaccine Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global 23-valent Pneumococcal Vaccine Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global 23-valent Pneumococcal Vaccine Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global 23-valent Pneumococcal Vaccine Sales Value by Region (2019-2024) & (%)
    Table 44. Global 23-valent Pneumococcal Vaccine Sales Value by Region (2025-2030) & (%)
    Table 45. Global 23-valent Pneumococcal Vaccine Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
    Table 46. Global 23-valent Pneumococcal Vaccine Sales Volume by Region (2019-2024) & (K Units)
    Table 47. Global 23-valent Pneumococcal Vaccine Sales Volume by Region (2025-2030) & (K Units)
    Table 48. Global 23-valent Pneumococcal Vaccine Sales Volume by Region (2019-2024) & (%)
    Table 49. Global 23-valent Pneumococcal Vaccine Sales Volume by Region (2025-2030) & (%)
    Table 50. Global 23-valent Pneumococcal Vaccine Average Price by Region (2019-2024) & (US$/Unit)
    Table 51. Global 23-valent Pneumococcal Vaccine Average Price by Region (2025-2030) & (US$/Unit)
    Table 52. Key Countries/Regions 23-valent Pneumococcal Vaccine Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions 23-valent Pneumococcal Vaccine Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions 23-valent Pneumococcal Vaccine Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions 23-valent Pneumococcal Vaccine Sales Volume, (2019-2024) & (K Units)
    Table 56. Key Countries/Regions 23-valent Pneumococcal Vaccine Sales Volume, (2025-2030) & (K Units)
    Table 57. Merck Company Information
    Table 58. Merck Introduction and Business Overview
    Table 59. Merck 23-valent Pneumococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 60. Merck 23-valent Pneumococcal Vaccine Product Offerings
    Table 61. Merck Recent Development
    Table 62. Sanofipasteur Company Information
    Table 63. Sanofipasteur Introduction and Business Overview
    Table 64. Sanofipasteur 23-valent Pneumococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 65. Sanofipasteur 23-valent Pneumococcal Vaccine Product Offerings
    Table 66. Sanofipasteur Recent Development
    Table 67. CDIBP Company Information
    Table 68. CDIBP Introduction and Business Overview
    Table 69. CDIBP 23-valent Pneumococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 70. CDIBP 23-valent Pneumococcal Vaccine Product Offerings
    Table 71. CDIBP Recent Development
    Table 72. Kexing Bio Company Information
    Table 73. Kexing Bio Introduction and Business Overview
    Table 74. Kexing Bio 23-valent Pneumococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 75. Kexing Bio 23-valent Pneumococcal Vaccine Product Offerings
    Table 76. Kexing Bio Recent Development
    Table 77. Changsheng Bio-Technology Company Information
    Table 78. Changsheng Bio-Technology Introduction and Business Overview
    Table 79. Changsheng Bio-Technology 23-valent Pneumococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 80. Changsheng Bio-Technology 23-valent Pneumococcal Vaccine Product Offerings
    Table 81. Changsheng Bio-Technology Recent Development
    Table 82. Huaan Science and Technology Innovation Company Information
    Table 83. Huaan Science and Technology Innovation Introduction and Business Overview
    Table 84. Huaan Science and Technology Innovation 23-valent Pneumococcal Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 85. Huaan Science and Technology Innovation 23-valent Pneumococcal Vaccine Product Offerings
    Table 86. Huaan Science and Technology Innovation Recent Development
    Table 87. Key Raw Materials Lists
    Table 88. Raw Materials Key Suppliers Lists
    Table 89. 23-valent Pneumococcal Vaccine Downstream Customers
    Table 90. 23-valent Pneumococcal Vaccine Distributors List
    Table 91. Research Programs/Design for This Report
    Table 92. Key Data Information from Secondary Sources
    Table 93. Key Data Information from Primary Sources
List of Figures
    Figure 1. 23-valent Pneumococcal Vaccine Product Picture
    Figure 2. Global 23-valent Pneumococcal Vaccine Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global 23-valent Pneumococcal Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global 23-valent Pneumococcal Vaccine Sales Volume (2019-2030) & (K Units)
    Figure 5. Global 23-valent Pneumococcal Vaccine Sales Price (2019-2030) & (US$/Unit)
    Figure 6. 23-valent Pneumococcal Vaccine Report Years Considered
    Figure 7. Global 23-valent Pneumococcal Vaccine Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global 23-valent Pneumococcal Vaccine Players Sales Volume Ranking (2023) & (K Units)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by 23-valent Pneumococcal Vaccine Revenue in 2023
    Figure 10. 23-valent Pneumococcal Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. Single Dose Vial Picture
    Figure 12. Pre-filled Syringe Picture
    Figure 13. Global 23-valent Pneumococcal Vaccine Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 14. Global 23-valent Pneumococcal Vaccine Sales Value Market Share by Type, 2023 & 2030
    Figure 15. Global 23-valent Pneumococcal Vaccine Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
    Figure 16. Global 23-valent Pneumococcal Vaccine Sales Volume Market Share by Type, 2023 & 2030
    Figure 17. Global 23-valent Pneumococcal Vaccine Price by Type (2019-2030) & (US$/Unit)
    Figure 18. Product Picture of Chronic Cardiovascular Disease
    Figure 19. Product Picture of Chronic Lung Disease
    Figure 20. Product Picture of Chronic Liver Disease
    Figure 21. Product Picture of People Living with Hiv
    Figure 22. Product Picture of Leukemia
    Figure 23. Product Picture of Lymphoma
    Figure 24. Product Picture of Multiple Myeloma
    Figure 25. Product Picture of General Malignancy
    Figure 26. Product Picture of Chronic Kidney Disease
    Figure 27. Product Picture of Other
    Figure 28. Global 23-valent Pneumococcal Vaccine Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 29. Global 23-valent Pneumococcal Vaccine Sales Value Market Share by Application, 2023 & 2030
    Figure 30. Global 23-valent Pneumococcal Vaccine Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
    Figure 31. Global 23-valent Pneumococcal Vaccine Sales Volume Market Share by Application, 2023 & 2030
    Figure 32. Global 23-valent Pneumococcal Vaccine Price by Application (2019-2030) & (US$/Unit)
    Figure 33. North America 23-valent Pneumococcal Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 34. North America 23-valent Pneumococcal Vaccine Sales Value by Country (%), 2023 VS 2030
    Figure 35. Europe 23-valent Pneumococcal Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 36. Europe 23-valent Pneumococcal Vaccine Sales Value by Country (%), 2023 VS 2030
    Figure 37. Asia Pacific 23-valent Pneumococcal Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 38. Asia Pacific 23-valent Pneumococcal Vaccine Sales Value by Country (%), 2023 VS 2030
    Figure 39. South America 23-valent Pneumococcal Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 40. South America 23-valent Pneumococcal Vaccine Sales Value by Country (%), 2023 VS 2030
    Figure 41. Middle East & Africa 23-valent Pneumococcal Vaccine Sales Value (2019-2030) & (US$ Million)
    Figure 42. Middle East & Africa 23-valent Pneumococcal Vaccine Sales Value by Country (%), 2023 VS 2030
    Figure 43. Key Countries/Regions 23-valent Pneumococcal Vaccine Sales Value (%), (2019-2030)
    Figure 44. Key Countries/Regions 23-valent Pneumococcal Vaccine Sales Volume (%), (2019-2030)
    Figure 45. United States 23-valent Pneumococcal Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 46. United States 23-valent Pneumococcal Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 47. United States 23-valent Pneumococcal Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 48. Europe 23-valent Pneumococcal Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 49. Europe 23-valent Pneumococcal Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 50. Europe 23-valent Pneumococcal Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 51. China 23-valent Pneumococcal Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 52. China 23-valent Pneumococcal Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 53. China 23-valent Pneumococcal Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 54. Japan 23-valent Pneumococcal Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 55. Japan 23-valent Pneumococcal Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 56. Japan 23-valent Pneumococcal Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 57. South Korea 23-valent Pneumococcal Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 58. South Korea 23-valent Pneumococcal Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 59. South Korea 23-valent Pneumococcal Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 60. Southeast Asia 23-valent Pneumococcal Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 61. Southeast Asia 23-valent Pneumococcal Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 62. Southeast Asia 23-valent Pneumococcal Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 63. India 23-valent Pneumococcal Vaccine Sales Value, (2019-2030) & (US$ Million)
    Figure 64. India 23-valent Pneumococcal Vaccine Sales Value by Type (%), 2023 VS 2030
    Figure 65. India 23-valent Pneumococcal Vaccine Sales Value by Application (%), 2023 VS 2030
    Figure 66. 23-valent Pneumococcal Vaccine Industrial Chain
    Figure 67. 23-valent Pneumococcal Vaccine Manufacturing Cost Structure
    Figure 68. Channels of Distribution (Direct Sales, and Distribution)
    Figure 69. Bottom-up and Top-down Approaches for This Report
    Figure 70. Data Triangulation
    Figure 71. Key Executives Interviewed

Description

The global market for 23-valent Pneumococcal Vaccine was estimated to be worth US$ 1440 million in 2023 and is forecast to a readjusted size of US$ 1938.4 million by 2030 with a CAGR of 4.4% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for 23-valent Pneumococcal Vaccine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of 23-valent Pneumococcal Vaccine by region & country, by Type, and by Application.

The 23-valent Pneumococcal Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding 23-valent Pneumococcal Vaccine.

Market Segmentation